Roche Goes Big On KRAS-Mutated Cancers In Hookipa Pact

Deal Snapshot: The Nobel Prize winner co-founded biotech can extend its cash runway into 2025, while Roche gains access to an immunotherapy with potential to treat a wide range of cancers.

Roche signed a deal with Hookipa worth $25m up front and up to $930m in milestones • Source: Shutterstock

More from Deals

More from Business